Thomson Reuters is influential in business circles where its...

Thomson Reuters is influential in business circles where its endorsement of NNZ-2566 will have a formative impact upon investors and potential collaborators.

Current price action in Neuren may reflect general investor impatience with biotech stocks particularly in a no news week (or month or quarter). The progress through the FDA process will require much stronger resolve from investors.

Is there light at the end of the tunnel? Sellers at 1.5c are presumably casting their vote. Personally, the opportunity to invest in Neuren which owns one of the 'five most promising drugs entering phase II trials,' together with a market cap of sub $10m, in the context of being fully funded through to the end of 2011, is absolutely compelling.